<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03510624</url>
  </required_header>
  <id_info>
    <org_study_id>s61580</org_study_id>
    <nct_id>NCT03510624</nct_id>
  </id_info>
  <brief_title>Acute Effect of Rebaudioside A on Glucose Excursion During an Oral Glucose Tolerance Test in Type 2 Diabetes Mellitus</brief_title>
  <acronym>AREBAG</acronym>
  <official_title>Investigation of the Acute Effect of Rebaudioside A on the Glucose Excursion During an Oral Glucose Tolerance Test in 30 Patients With Type 2 Diabetes Mellitus (AREBAG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate the acute effect of the steviol glycoside, rebaudioside A, on the glucose&#xD;
      excursion during an oral glucose tolerance test in 30 patients with type 2 diabetes mellitus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible individuals with type 2 diabetes mellitus will be invited for four study visits.&#xD;
      During the first and third study visit, rebaudioside A or the placebo will be administered.&#xD;
      During the second and fourth study visit, an oral glucose tolerance test (OGTT) will be&#xD;
      executed to measure the response of administration of rebaudioside A versus placebo on the&#xD;
      glucose homeostasis. The area under the curve blood glucose values during the first two hours&#xD;
      of the OGTT will be compared for both conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 9, 2018</start_date>
  <completion_date type="Actual">April 1, 2021</completion_date>
  <primary_completion_date type="Actual">April 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC) blood glucose concentrations during an OGTT</measure>
    <time_frame>0 to 2 hours after glucose challenge</time_frame>
    <description>Area under the curve blood glucose concentrations during an OGTT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC glucose/insulin/glucagon</measure>
    <time_frame>-30 to 0 min of OGTT</time_frame>
    <description>AUC glucose/insulin/glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC glucose/insulin/glucagon</measure>
    <time_frame>0 to 30 min of OGTT</time_frame>
    <description>AUC glucose/insulin/glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC glucose/insulin/glucagon</measure>
    <time_frame>0 to 4 hours of OGTT</time_frame>
    <description>AUC glucose/insulin/glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal blood glucose</measure>
    <time_frame>-30 min to 4 hours of OGTT</time_frame>
    <description>Maximal blood glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal blood glucose excursion</measure>
    <time_frame>-30 min to 4 hours of OGTT</time_frame>
    <description>Maximal blood glucose excursion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal serum insulin</measure>
    <time_frame>-30 min to 4 hours of OGTT</time_frame>
    <description>Maximal serum insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal serum glucagon</measure>
    <time_frame>-30 min to 4 hours of OGTT</time_frame>
    <description>Maximal serum glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration(t) (C(t))rebaudioside A, steviol and steviol glucuronide</measure>
    <time_frame>-30 min to 4 hours of OGTT</time_frame>
    <description>Concentration of rebaudioside A, steviol and steviol glucuronide on different time points</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>First rebaudioside A and then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>First placebo and then rebaudioside A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rebaudioside A</intervention_name>
    <description>Rebaudioside A 3g</description>
    <arm_group_label>First placebo and then rebaudioside A</arm_group_label>
    <arm_group_label>First rebaudioside A and then placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Empty capsules</description>
    <arm_group_label>First placebo and then rebaudioside A</arm_group_label>
    <arm_group_label>First rebaudioside A and then placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated written informed consent&#xD;
&#xD;
          -  Understand procedures&#xD;
&#xD;
          -  Type 2 diabetes mellitus&#xD;
&#xD;
          -  Body Mass Index (BMI): 25 - 40 kg/m2&#xD;
&#xD;
          -  HbA1c: 6.5-8%&#xD;
&#xD;
          -  Judged to be in good health&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is unable to&#xD;
&#xD;
               -  Refrain from stevia leaves, stevia extracts or steviol glycoside-containing&#xD;
                  products from 5 days prior to administration of rebaudioside A or placebo until&#xD;
                  discharge from the unit after the OGTT on the consecutive day.&#xD;
&#xD;
               -  Refrain from quinine-containing products from 72h prior to administration of&#xD;
                  rebaudioside A or placebo until discharge from the unit after the OGTT on the&#xD;
                  consecutive day.&#xD;
&#xD;
               -  Maintain their habitual diets and physical activity patterns and refrain from&#xD;
                  engaging in strenuous physical activities from 72h prior to administration of&#xD;
                  rebaudioside A or placebo until discharge from the unit after the OGTT on the&#xD;
                  consecutive day.&#xD;
&#xD;
               -  Refrain from grapefruit products from 14 days before study visit 1 until&#xD;
                  discharge from the unit after the OGTT on study visit 4.&#xD;
&#xD;
               -  Refrain from alcohol from 24h prior to administration of rebaudioside A or&#xD;
                  placebo until discharge from the unit after the OGTT on the consecutive day.&#xD;
&#xD;
               -  Refrain from caffeine containing products from 12h prior to administration of&#xD;
                  rebaudioside A or placebo until discharge from the unit after the OGTT on the&#xD;
                  consecutive day.&#xD;
&#xD;
               -  Fast at least 5 hours prior to the administration of rebaudioside A or placebo on&#xD;
                  study days 1 and 3.&#xD;
&#xD;
               -  Fast at least 10 hours prior to the study days 2 and 4.&#xD;
&#xD;
          -  Women of childbearing potential (last menstruation less than 1 year prior to&#xD;
             screening) who are pregnant, lactating or planning to become pregnant during the&#xD;
             study.&#xD;
&#xD;
          -  Individuals with other forms of diabetes&#xD;
&#xD;
          -  Current or previous treatment with any diabetes drug within 3 months prior to&#xD;
             screening, except for metformin.&#xD;
&#xD;
          -  Symptomatic hyperglycemia requiring immediate therapy during screening, in the&#xD;
             judgement of the principal investigator.&#xD;
&#xD;
          -  Evidence of significant diabetic complications.&#xD;
&#xD;
          -  History of pancreas or beta-cell transplantation.&#xD;
&#xD;
          -  Presence or history of clinically relevant medical, surgical or psychiatric conditions&#xD;
             likely to affect the subject's safety in this trial or that could confound the study&#xD;
             assessments or endpoints.&#xD;
&#xD;
          -  Clinically relevant abnormal physical findings.&#xD;
&#xD;
          -  Clinically significant abnormalities of vital signs:&#xD;
&#xD;
               -  Seated systolic blood pressure outside 90-160 mmHg&#xD;
&#xD;
               -  Diastolic blood pressure outside 40-100 mmHg&#xD;
&#xD;
               -  Heart rate &lt;50 bpm&#xD;
&#xD;
               -  Corrected QT (QTC) using Fridericia's formulae &gt;450 msec (for men) or &gt;470 msec&#xD;
                  (for women) measured with a 12-lead electrocardiogram.&#xD;
&#xD;
               -  Clinically significant abnormal laboratory values.&#xD;
&#xD;
               -  Moderate or severe renal dysfunction defined as a calculated glomerular&#xD;
                  filtration rate (GFR) &lt;30 ml/min.&#xD;
&#xD;
          -  Currently active or history of alcohol abuse.&#xD;
&#xD;
          -  Currently active or history of drug addiction or currently a regular user of drugs&#xD;
             including &quot;recreational use&quot; of any illicit drug.&#xD;
&#xD;
          -  Smoking cigarettes or using nicotine-containing products, during the last 6 months&#xD;
             prior to screening, as nicotine inhibits the Transient Receptor Potential 5 (TRPM5)&#xD;
             channel.&#xD;
&#xD;
          -  Individuals for whom a major surgery is planned to occur between screening and the end&#xD;
             of the trial.&#xD;
&#xD;
          -  Previous or current use of concomitant medication, which would confound the study&#xD;
             conduct or implicate a risk for safety of the participant, as judged by the&#xD;
             investigator(s).&#xD;
&#xD;
          -  History of relevant drug or food allergies or a history of severe anaphylactic&#xD;
             reaction.&#xD;
&#xD;
          -  History of hypersensitivity to the study drug or any of the excipients or to medicinal&#xD;
             products with similar chemical structures.&#xD;
&#xD;
          -  Individuals with hepatitis B and/or hepatitis C virus.&#xD;
&#xD;
          -  Individuals with Human Immunodeficiency Virus (HIV).&#xD;
&#xD;
          -  Participation in another clinical trial involving an investigational product within&#xD;
             the 3 months preceding screening or 5-halflives of the drug studied, whichever is&#xD;
             longer, prior to study supplement administration. Or, participation in any other type&#xD;
             of medical research within 3 months preceding screening judged not to be&#xD;
             scientifically or medically compatible with this study.&#xD;
&#xD;
          -  Individuals who have donated or lost more than 500 ml blood or plasma within 3 months&#xD;
             prior to screening.&#xD;
&#xD;
          -  Individuals unable to swallow orally administered medication.&#xD;
&#xD;
          -  Individuals in which catheter placement is impossible (amputation, no visible veins,&#xD;
             â€¦)&#xD;
&#xD;
          -  Individuals that cannot speak or understand the Dutch language.&#xD;
&#xD;
          -  In the opinion of the principal investigator any other factor that could interfere&#xD;
             with the subject's ability to provide informed consent or to complete the study with&#xD;
             strict compliance to the study protocol, or that could hold safety concerns for the&#xD;
             subject or could impact the outcome of the study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bart Van der Schueren</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centrum Clinical Pharmacology</name>
      <address>
        <city>Leuven</city>
        <state>Flanders</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 17, 2018</study_first_submitted>
  <study_first_submitted_qc>April 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2018</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

